News
News from Peptinovo Biopharma
Press Releases, News and More.
Delivering Chemotherapy Drugs Directly into Cancer Cells While Minimizing Harm
Peptinovo Biopharma’s Targeted Cancer Drug Platform Approved for Clinical Trials
Peptinovo Biopharma, an Ann Arbor–based biotechnology company pioneering targeted cancer therapies through its first-of-its-kind proprietary PALM™ nanotechnology, today announced it has received approval to initiate its first human clinical trials ...
Peptinovo Biopharma in Collaboration with Chemelectiva Announces Breakthrough Manufacturing Innovation for Targeted Chemotherapy
Peptinovo Biopharma, an Ann Arbor-based biotechnology company pioneering targeted cancer therapies through its proprietary PALM™ nanotechnology, today announced a major manufacturing and intellectual property milestone achieved in collaboration with Chemelectiva ...
Peptinovo Biopharma Partners with Alcami to Advance Novel Cancer Nanotechnology and Enable Global Distribution
Peptinovo Biopharma, an Ann Arbor–based biotechnology company pioneering targeted cancer therapies through its proprietary PALM™ nanotechnology, today announced a strategic partnership with Alcami Corporation, a leading U.S.-based contract development and ...
Peptinovo Biopharma Selects Ardena as Manufacturing Partner to Advance Its Novel Cancer Nanotechnology Toward Clinical Trials
Peptinovo Biopharma, a biotechnology company pioneering targeted cancer therapies through its proprietary PALM™ nanotechnology, announced a strategic manufacturing partnership with Ardena, a specialist pharmaceutical contract development and manufacturing organization (CDMO) ...
Founder’s Story: Ren Homan
Dr. Ren Homan, Chief Scientific Officer and President of Peptinovo Biopharma, has had an extensive and dynamic career in the biopharmaceutical industry. From its inception to the clinic, Peptinovo and ...
Peptinovo Biopharma raises $1.4 million in Series A funding, begins campaign to raise $10 million to enhance cancer treatment
[Press Release] Peptinovo Biopharma, an Ann Arbor-based biopharma company, has successfully closed $1.4 million in funding as part of its Series A round. The milestone kicks off a campaign to ...